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Abstract
Background: No data regarding metformin effects on follicular fluid anti-Müllerian hormone (AMH) levels were to
date available in literature. The aim of the present study was to evaluate in patients with polycystic ovary
syndrome (PCOS) whether metformin administration affects serum and follicular AMH levels, and whether this is
related to ovarian response to the treatment.
Methods: Twenty young patients with PCOS who had received metformin were enrolled. Ten patients were
anovulatory (Met-anov group), whereas the other 10 were ovulatory (Met-ov group) but had failed to conceive.
Further untreated PCOS (PCOS controls, n. 10) and healthy controls (non-PCOS controls, n. 10) who were scheduled
for laparoscopic surgery were enrolled. In each subjects, clinical and biochemical evaluations were performed. AMH
concentrations in blood and antral follicular fluid were assayed.
Results: In both Met-anov and Met-ov groups, and without difference between them, serum androgens and AMH,
and indices of insulin resistance were significantly (p < 0.05) improved after treatment. On the other hand,
significant differences (p < 0.05) between the two groups were detected with respect to the same biochemical
parameters in antral follicular fluid. In the Met-anov group, no significant correlation was observed between AMH
concentrations in the follicular fluid and variation in serum androgens, AMH and insulin resistance indexes; whereas
in Met-ov group significant correlations were detected between AMH levels in the follicular fluid and variation in
serum androgens, AMH and insulin resistance indexes.
Conclusions: Metformin administration in patients with PCOS exerts a differential action on the ovarian AMH levels
on the basis of ovulatory response. Changes in AMH levels in antral follicular fluid during metformin treatment
could be involved in the local mechanisms mediating the ovulatory restoration.
Background
Anti-Müllerian hormone (AMH) is a member of the
transforming growth factor-b (TGF-b) family. In
females, AMH is mainly secreted by the granulosa cells
of ovarian early developing follicles [1].
The expression of AMH is localized in granulosa cells
of primary, pre-antral and small antral follicles, suggest-
ing an important role of AMH in human folliculogenesis
[2]. Since AMH is secreted exclusively in the gonads, its
serum concentrations in females are thought to reflect
the size of the ovarian follicle pool [2,3].
Polycystic ovary syndrome (PCOS), one of the most
common endocrine disorders in women of childbearing
age [4-6], is characterized by a marked increase in pre-
antral follicles number [7]. To date, controversial data
are available regarding the relationship between the high
serum AMH levels and the pre-antral follicles number
in PCOS patients [8-12]. Thus, is still unknown if the
AMH excess in PCOS is secondary to the increase in
pre-antral follicles number, or if an intrinsic increased
AMH production by the granulosa cells is the cause of
follicular arrest in PCOS.
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counts and ovarian volume with hyperinsulinemia was
referred in PCOS women [13,14]. Furthermore, it is
unclear if the PCOS-related hyperinsulinemic state
could induce the development of antral follicles by
increasing the sensitivity of granulosa cells to FSH
determining an higher number of follicles and a major
ovarian volume [15-17].
Metformin, an insulin-sensitizing drugs recently intro-
duced for the treatment of women with PCOS, has been
demonstrated to induce regular menstrual cycles and to
increase ovulation in patients with PCOS, although the
efficacy of the drug is extremely variable both between
different PCOS populations and within the same popu-
lation [18].
A recent experimental study was conducted with the
aim to evaluate whether the efficacy of metformin in
patients with PCOS is related to a systemic hormonal-
metabolic improvement or to a local action on the
ovary [19]. The authors found that, irrespectively to
systemic effects, the efficacy of metformin in inducing
ovulation in patients with PCOS was probably due
to a direct action of the drug on a “sensitive” ovary.
At the moment, the few studies aimed to assess the
effects of metformin administration in PCOS patients
on serum AMH levels reported controversial findings
[9,20-22], and any data is actually available in literature
regarding the metformin effects on follicular fluid AMH
levels. Based on these considerations, the aim of the pre-
sent study was to evaluate in patients with PCOS
whether metformin administration affects serum and
follicular AMH levels, and whether this effect is related
to ovarian response to the treatment.
Methods
The study was approved by the Institutional Review
Board of the Department of Obstetrics and Gynecology,
University “Magna Graecia” of Catanzaro, Italy. The
purpose of the protocol was explained carefully to all
the patients and written consent was obtained before
the study began.
Twenty young normal weight patients with PCOS who
had received metformin treatment to induce ovulation
and, then, scheduled for laparoscopy were enrolled at
our Academic Centre of Reproductive Medicine and
Surgery between October 2001 and February 2010, and
studied as cases. The majority of the subjects had parti-
cipated in our earlier studies [19,23].
All patients with PCOS had received the same metfor-
min regimen (two 850 mg tablets daily) for one year.
On the basis of the response to treatment received,
cases were distinguished according to ovarian response
to metfomin into two groups (Met-anov and Met-ov
groups). Specifically, Met-anov group (n. 10) was
composed of PCOS patients who remained anovulatory
despite treatment, and Met-ov group (n. 10) included
PCOS women who resulted normally cycled under met-
formin treatment (for at least six cycles) but had failed
to conceive.
According to our Institutional guidelines, subjects
from the Met-anov group were scheduled for ovarian
drilling procedure, whereas subjects from the Met-ov
group were scheduled for diagnostic laparoscopy in
order to exclude potential infertility/subfertility factors.
Other 20 patients were enrolled as controls. Of them,
10 were untreated patients with PCOS [24,25], affected
by uterine fibroids and scheduled for laparoscopic myo-
mectomy (PCOS controls), whereas other 10 normally
cycled women were scheduled for diagnostic laparo-
scopy because they referred chronic pelvic pain (non-
PCOS controls).
In PCOS patients, PCOS diagnosis was based initially
on the presence of both chronic anovulation and clinical
and/or biochemical hyperandrogenism [25], even if all
patients with PCOS originally had bilateral polycystic
ovaries (PCO) [24]. In healthy controls, ovulatory cycles
were confirmed by biochemistry, and clinical and/or
biochemical hyperandrogenism and PCO were systema-
tically excluded.
Were considered exclusion criteria for all subjects: an
age less than 18 or greater than 35 years; a body mass
index (BMI, kg/m
2) less than 18 or greater than 25;
major medical disorders and/or current or previous use
of hormonal and/or metabolic drugs; tubal or male fac-
tor infertility or sub-fertility investigated with hysterosal-
pingography and standard semen analysis, respectively
(Male Infertility Best Practice Policy Committee of the
American Urological Association, 2006; Practice Com-
mittee of the American Society for Reproductive Medi-
cine 2006); any organic pelvic diseases at laparoscopy or
diseases potentially affecting the ovarian environment
and/or function (including endometriosis, leiomyomas,
and so on); and the intention to start a diet or a specific
programme of physical activity. In addition, subjects
with dominant follicle(s) (follicles with a diameter equal
or higher than 10 mm) and/or with persistent corpora
lutea and/or functional cysts at transvaginal ultrasound
performed before surgery were excluded. Clinical, bio-
chemical, and ultrasonographic parameters at baseline
or before metformin administration were acquired retro-
spectively, whereas all other data were evaluated pro-
spectively at the hospital admission.
Clinical evaluation, blood sampling, transvaginal ultra-
sonography, and laparoscopy were performed in each
subject. Clinical evaluation consisted of gynecological
examination, anthropometric measurements and Ferri-
man-Gallwey score calculation. Biochemical assessment
consisted of complete hormonal, including evaluation of
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hormone (LH), thyroid-stimulating hormone (TSH),
prolactin (PRL), estradiol (E2), P, 17-OH-progesterone
(17-OHP), total testosterone (T), androstenedione (A),
dehydroepiandrosterone sulfate (DHEAS), and sex-hor-
mone binding globulin (SHBG)], and metabolic evalua-
tion, including evaluation of fasting glucose and insulin
levels. Insulin resistance was evaluated using the homeo-
stasis model analysis (HOMA) [fasting glucose (mmol/L)
× fasting insulin (μU/mL)/22.5] and the fasting glucose-
to-insulin ratio (GIR, mg/10
-4U). The free androgen
index (FAI) [T (nmol/l)/SHBG × 100] was also calcu-
lated for each participant.
Serum and follicular fluid AMH levels were assessed
by using a second generation enzyme immunoassay
(AMH-EIA kit; Immunotech A Beckman Coulter Com-
pany, Marseilles, France), according to the supplier’s
instructions. The intra-assay and inter-assay coefficients
of variation (CV) for each biochemical or hormonal
parameter were evaluated, and the values of the CVs
ranged from 1.2 to 5.8%.
Finally, the ovarian dimensions, volume and morphol-
ogy and the number of antral follicles (follicular dia-
meter ranged from 2 to 9 mm) were evaluated
bilaterally by transvaginal ultrasonography. The antral
follicle number per ovary, defined as the average for the
total number of antral follicles counted from both ovar-
ies, was also calculated.
All laparoscopic interventions were performed by the
same experienced operator (F.Z.) during the early folli-
cular phase for ovulatory subjects and randomly in ano-
vulatory patients. Firstly, the antral follicles on the
ovarian surface were visualized and each one was aspi-
rated with a 1 mL syringe and a 26 gauge needle. Folli-
cular fluid of antral follicles was collected from both
ovaries in each patient, it was transferred to the labora-
tory on dry ice, and purified from the granulosa cells.
Thereafter, the remaining follicular fluid was centri-
fuged, and the supernatant was stored at -20°C until it
underwent biochemical analysis.
As scheduled, ovarian diathermy and myomectomy
were performed in Met-anov and PCOS control group,
respectively.
Statistical analysis
Continuous variables were tested for normality using the
Kolmogrov-Smirnov test resulting normally distributed
and were expressed as the mean ± standard deviation
(SD).
Data were analyzed with one-way analysis of variance
(ANOVA) and ANOVA for repeated measures, and the
Bonferroni test was used for post-hoc analysis.
For categorical variables, the Pearson chi-square test
was performed; Fisher’se x a c tt e s tw a su s e df o rt h e
frequency tables when more than 20% of the expected
values were lower than five.
A simple linear regression analysis was used to estab-
lish the relationships between the AMH in the follicular
fluid, and the variation (Δ) in plasma T levels (ΔT),
HOMA (ΔHOMA), and AMH (ΔAMH). A bivariate
two-tailed correlation analysis was performed by calcu-
lating the Spearman’s coefficient (Spearman’sr h o ,r ) ,
and the significance of the correlation was set at the
0.05 level.
The level of statistical significance was set at p <0 . 0 5
for all statistical analyses. The Statistics Package for
Social Sciences (SPSS 14.0.1, 18 Nov 2005; SPSS Inc.,
Chicago, IL) was used for all calculations.
Results
The criteria of the National Institutes of Health (NIH),
the criteria of the European Society for Human Repro-
duction (ESHRE)/American Society of Reproductive
Medicine (ASRM) [5] and those of the Androgen Excess
& PCOS Society (AEPS) [26] were all satisfied in our
sample.
The clinical, hormonal, and metabolic data from all
groups at baseline and their variation after treatment are
shown in Table 1.
In both Met-anov and Met-ov groups, levels of T, A,
SHBG, and fasting insulin, as well as FAI, GIR, HOMA,
and AMH were improved significantly (p< 0.05) after
treatment.
A significant difference (p < 0.05) between Met-anov
and Met-ov groups was observed at baseline and after
metformin with regards to the serum levels of SHBG,
fasting insulin, GIR, HOMA, and AMH before treat-
ment (Table 1).
In both Met-anov and Met-ov groups, serum levels of
LH, T, A, DHEAS, SHBG, fasting insulin, and AMH as
well as the Ferriman-Gallwey score, FAI, GIR and
HOMA, were significantly (p < 0.05) better than those
in PCOS controls and significantly (p < 0.05) worse than
those in non-PCOS controls (Table 1).
No difference in the mean variation of any clinical,
hormonal or metabolic parameter was observed between
Met-anov and Met-ov groups (Table 1).
In Figure 1 are shown the AMH concentrations in the
follicular fluid of the antral follicles. Significant differ-
ences (p < 0.05) were observed between Met-anov and
Met-ov groups in AMH levels in the antral follicular
fluid (Figure 1). Moreover, AMH levels in the antral fol-
licles were significantly different (p < 0.05) for both
Met-anov group vs. PCOS controls and Met-ov group
vs. non-PCOS controls (Figure 1).
The correlations between AMH levels in the follicular
fluid and ΔT, ΔHOMA and ΔAMH, in Met-anov and
Met-ov groups are shown in Table 2.
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concentrations in the follicular fluid, and ΔT, ΔHOMA
and ΔAMH, in the Met-anov group. On the contrary,
significant correlations were detected between AMH
levels in the follicular fluid and ΔT( r = -0.701; p =
0.039), ΔHOMA (r = 0.645; p = 0.044), and ΔAMH (r =
-0.821; p = 0.026).
Discussion
The present experimental study firstly evaluated the effect
of metformin administration on AMH concentrations
assayed both on serum and follicular fluid in women
affected by PCOS. Our data confirmed [27,28] that AMH
levels were significantly higher in PCOS patients than in
healthy controls. A plausible hypothesis for this figure is
that the increased AMH levels in PCOS are the results of
the increased number of small ovarian follicles [29,30]. In
this regard, a direct and a significant correlation between
follicle number and serum AMH levels has been demon-
strated by some authors [8-10,12], even if the hypotheses
provided for this correlation were not univocal [27,28].
Interesting results were obtained by the evaluation of
AMH levels in PCOS women who were treated with
metformin. In particular, we used as study model PCOS
patients who had a different response to metformin
administration in order to clarify the role of AMH in
the ovarian response to the treatment.
Table 1 Clinical, hormonal, and metabolic data in Met-anov and Met-ov groups, and in PCOS and non-PCOS controls
Group Met-anov Met-ov PCOS controls Non-PCOS controls
Before treatment Δ Before treatment Δ
Age (years) 27.40 ± 3.21 0.12 ± 0.15 28.08 ± 3.45 0.08 ± 0.29 27.83 ± 3.61 28.17 ± 3.58
BMI (kg/m
2) 23.00 ± 1.58 -0.11 ± 0.25 22.97 ± 1.37 -0.06 ± 0.10 22.84 ± 1.64 23.09 ± 1.58
WHR 0.76 ± 0.12 0.01 ± 0.02 0.77 ± 0.10 -0.00 ± 0.06 0.76 ± 0.10 0.75 ± 0.98
Ferriman-Gallwey score 12.67 ± 2.70° -1.84 ± 0.45 12.42 ± 2.43° -0.09 ± 0.03 12.0 ± 2.98° 3.25 ± 1.91
FSH (mIU/mL) 5.85 ± 1.57 0.06 ± 0.03 5.86 ± 1.32 -0.03 ± 0.04 6.04 ± 1.39 5.50 ± 1.60
LH (mIU/mL) 11.89 ± 3.87° -0.12 ± 0.31 12.56 ± 3.45° -0.76 ± 0.25 12.56 ± 3.48° 10.43 ± 2.48
TSH (μU/mL) 2.94 ± 0.75 -0.02 ± 0.07 2.99 ± 0.72 -0.06 ± 0.05 2.81 ± 0.77 3.01 ± 0.65
PRL (ng/mL) 8.90 ± 2.13 0.08 ± 0.13 9.17 ± 1.83 1.26 ± 0.06 8.26 ± 2.13 9.20 ± 1.93
E2 (pg/mL) 52.45 ± 16.43 0.53 ± 18.60 49.79 ± 14.98 0.26 ± 0.08 50.18 ± 11.00 52.24 ± 8.65
P (ng/mL) 1.38 ± 0.43 -0.02 ± 0.04 1.33 ± 0.44 -0.11 ± 0.09 1.40 ± 0.42 1.42 ± 0.36
17-OHP (μg/L) 2.25 ± 0.50 -0.28 ± 0.07 2.06 ± 0.46 -0.13 ± 0.07 2.20 ± 0.47 1.85 ± 0.41
T (ng/mL) 4.65 ± 1.15° -1.14 ± 0.19 4.62 ± 1.13° -0.35 ± 0.12 4.71 ± 1.02° 1.10 ± 0.29
A (ng/mL) 4.82 ± 1.91° -1.63 ± 0.08 4.40 ± 1.13° -0.20 ± 0.08 4.80 ± 1.14° 1.84 ± 0.45
DHEAS (ng/mL) 2674.10 ± 189.7° -9.8 ± 0.25 2703.43 ± 204.42° -17.55 ± 0.11 2696.66 ± 215.77° 1792.50 ± 253.84
SHBG (nmol/L) 32.41 ± 3.35°† 0.49 ± 0.32 30.41 ± 1.88° 0.75 ± 1.06 30.50 ± 2.20° 49.45 ± 5.96
FAI (%) 14.50 ± 4.13° -4.24 ± 1.39 14.63 ± 4.06° -4.57 ± 0.07 14.78 ± 5.20° 3.73 ± 1.44
Fasting glucose (mmol/L) 4.60 ± 0.49 -0.35 ± 0.06 4.61 ± 0.47 -0.08 ± 0.08 4.52 ± 0.50 4.65 ± 0.46
Fasting insulin (μU/mL) 16.20 ± 4.82°† -0.53 ± 0.22 16.51 ± 3.57° -2.31 ± 0.11 16.30 ± 4.39° 14.36 ± 2.07
GIR (mg/10
-4U) 5.64 ± 1.18°† 0.36 ± 0.10 5.40 ± 1.59° 1.17 ± 0.14 5.21 ± 1.41° 7.45 ± 1.24
HOMA 3.20 ± 0.61°† -0.04 ± 0.17 3.73 ± 0.61° -0.41 ± 0.11 3.17 ± 0.69° 2.90 ± 0.71
AMH (ng/mL) 5.23 ± 1.59°† -2.0 ± 1.05 5.75 ± 1.59° -7.41 ± 2.32 3.92 ± 1.62° 1.56 ± 1.02
*p < 0.05 vs. before treatment assessment; †p < 0.05 vs. Met-ov group; ^p < 0.05 vs. PCOS controls; °p < 0.05 vs. non-PCOS controls.
Figure 1 AMH levels in the follicular fluid of the antral follicles.
†p < 0.05 vs. Met-ov group; ^p < 0.05 vs. PCOS controls; °p < 0.05
vs. non-PCOS controls.
Table 2 Linear correlation between AMH concentrations
in the follicular fluid, and variation (Δ) in serum T, HOMA
and AMH, in the Met-anov and Met-ov groups
Met-anov group
(n = 10)
Met-ov group
(n = 10)
rp r p
Follicular fluid AMH
ΔT -0.543 0.213 -0.701 0.039
ΔHOMA 0.121 0.185 0.645 0.044
ΔAMH -0.543 0.315 -0.821 0.026
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AMH might play a key role in the intra-ovarian
mechanisms regulating the ovarian function. In fact, sig-
nificant changes in serum AMH levels in PCOS patients
ovulating under metformin, such as in those remaining
anovulatory despite treatment were detected. The reason
for the reduction in AMH concentrations after metfor-
min remains still controversial.
In a prospective study [20], metformin acutely
improved insulin resistance indexes and restored ovarian
morphology, whereas no effect of the metformin-
induced improved insulin-sensitivity and AMH levels
was observed. These data [20] are strongly limited by
the very small sample size and the short-term observa-
tion period. Moreover, Piltonen et al. [9], in a prospec-
tive study, showed that the AMH levels, the number of
antral follicles and the ovarian volume were reduced
after metformin administration. In addition, a positive
correlation was found between serum AMH levels and
both follicle count and androgen levels [9]. These corre-
lations were successively confirmed [12], and a further
relationship between AMH levels and insulin resistance
indexes was demonstrated in untreated PCOS patients.
On the other hand, in a recent prospective, randomized,
double-blind 26 week long-term study [21], AMH levels
in untreated PCOS women seemed to be associated
positively with testosterone, and negatively with DHEAS
and C-peptide levels. Moreover, the same authors
showed that 6 months of androgen suppression by
either metformin or low-dose dexamethasone treatment
failed to influence circulating AMH levels [21].
The current study, confirming and extending our pre-
vious data [31], suggests that metformin acts on ovarian
AMH levels with additive and direct mechanism of
action. In fact, the effects of metformin at ovarian site
did not reflect those observed at systemic levels. Signifi-
cant difference in intraovarian AMH levels was observed
within PCOS patients who received metformin on the
basis of clinical response, even if women ovulating
under metformin maintained higher follicular AMH
levels than healthy controls. Thus, it is possible to
hypothesize that metformin exerts a peripheral effect on
the ovary by lowering AMH concentration that is detri-
mental for clinical response to the treatment. On the
other hand, a slight effect on follicular AMH level was
also observed in unresponsive PCOS patients, in fact
significant difference in AMH levels was observed
between anovulatory PCOS women who had received
metformin and untreated anovulatory PCOS patients.
A simple linear regression analysis was performed to
establish the relationship between AMH in the follicular
fluid and the systemic response to the treatment, which
included ΔTa n dΔHOMA as indicators for improved
hyperandrogenism and insulin resistance, respectively,
and serum ΔAMH.
As already shown [32], ovaries in our population with
PCOS seemed to have a differential sensitivity to metfor-
min, and that an improved biochemical response to met-
formin by a “sensitive” ovary could be decisive for the
clinical response mediated by AMH. In this regard, ovula-
tory patients with PCOS had significant correlations
between the AMH levels in follicular fluid and the varia-
tion in plasma T and AMH levels and the variation in
HOMA, respectively. On the contrary, patients with PCOS
who were anovulatory under metformin seemed to have a
local “resistance” to the treatment, and no significant cor-
relation between the variation in any systemic factors and
follicular AMH levels was observed in these patients.
Conclusions
Metformin administration in anovulatory patients with
PCOS exerts a differential action on the ovarian AMH
levels on the basis of ovulatory response. Changes in
AMH levels in antral follicular fluid during metformin
treatment could be involved in the local mechanisms
mediating the ovulatory restoration. Further well
designed studies on a larger sample are needed before
obtaining definitive conclusions.
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